Sava Infond d.o.o. Has $388,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Sava Infond d.o.o. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.5% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 740 shares of the biopharmaceutical company’s stock after selling 60 shares during the quarter. Sava Infond d.o.o.’s holdings in Regeneron Pharmaceuticals were worth $388,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of REGN. Nuveen LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $343,764,000. Pacer Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock worth $258,366,000 after purchasing an additional 390,374 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in Regeneron Pharmaceuticals by 171.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company’s stock worth $305,311,000 after purchasing an additional 303,785 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Regeneron Pharmaceuticals by 18.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock worth $724,984,000 after purchasing an additional 174,056 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock worth $5,966,767,000 after purchasing an additional 121,545 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $600.00 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,024.36. The firm has a 50 day moving average price of $572.12 and a two-hundred day moving average price of $567.94. The stock has a market cap of $63.59 billion, a P/E ratio of 15.12, a price-to-earnings-growth ratio of 1.92 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. During the same period in the prior year, the company posted $11.56 EPS. The company’s revenue was up 3.6% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.87%.

Analysts Set New Price Targets

REGN has been the subject of several analyst reports. UBS Group reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Jefferies Financial Group lifted their price objective on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research note on Wednesday, August 27th. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price objective for the company. in a research note on Friday, August 1st. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Finally, Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.